Saulnier Mark G

TL;DR: In this paper, a method for the delivery of cytotoxic drugs to tumor cells by the administration of a tumor-specific antibody-enzyme conjugate that binds to the tumor cells, and the additional administration of an additional prodrug that is converted at the tumor site, in the presence of the antibody-bound enzyme, to an active cytotoxicity drug.

TL;DR: Two anti-tumor monoclonal antibodies, L6 (anticarcinoma) and 1F5 (anti-B lymphoma), were covalently linked to alkaline phosphatase (AP), forming conjugates that could bind to the surface of antigen-positive tumor cells, capable of converting a relatively noncytotoxic prodrug into etoposide--a drug with significant antitumor activity.

TL;DR: A novel animal model that involves transgenic expression of a fusion receptor that is constitutively activated by homodimerization is described that should provide new opportunities for further understanding how aberrant IGF-IR signaling leads to tumorigenesis and for optimizing novel antagonists of the receptor kinase.

TL;DR: BMS-554417 is a member of a novel class of IGF-IR/insulin receptor inhibitors that have potential clinical applications because of their antiproliferative and proapoptotic activity in vitro and in vivo.

TL;DR: Compound 3 (BMS-536924), a novel small-molecule inhibitor of the insulin-like growth factor receptor kinase with equal potency against the insulin receptor is described.